Document is current

Article History

First Online: 18 December 2025

Competing interests

: Y.Y.J. declares research funding from Astellas, AstraZeneca, Arcus Biosciences, Bayer, Bristol-Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly, Fred’s Team, Genentech/Roche, Inspirna, Merck, NCI, Stand Up 2 Cancer and Transcenta; advisory boards and/or consulting for Abbvie, Alphasights, Amerisource Bergen, Ask-Gene Pharma, Inc., Arcus Biosciences, Astellas, AstraZeneca, Basilea Pharmaceutica, Bayer, BeOne, Boehringer Ingelheim, Bristol-Myers Squibb, Clinical Care Options, Daiichi-Sankyo, Debbie’s Dream Foundation, eChina Health, Ed Med Resources (OncInfo), Eisai, Eli Lilly, Geneos Therapeutics, Gilead Sciences, GlaxoSmithKline, Guardant Health, Inc., H.C. Wainwright & Co., Health Advances, HMP Global, I3Health, Imedex, Imugene, Inspirna, Lynx Health, Mashup Media LLC, Master Clinician Alliance, Merck, Merck Serono, Mersana Therapeutics, Michael J. Hennessy Associates, Oncology News, OncoDaily, Paradigm Medical Communications, PeerMD, PeerView Institute, Pfizer, Physician’s Education Resource, LLC, Research to Practice, Sanofi Genzyme, Seagen, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co., Ltd, Talem Health, TotalCME, WebMD and Zymeworks Inc.; and stock options in Inspirna, Veda Life Sciences, Inc. and OncoDaily. O.M.F. declares travel expenses for Novartis and AstraZeneca.